Novanta Posts Double-Digit Q4 Growth, Bookings Up 17% as Shorts Surge
In Q4 2025 Novanta’s Advanced Surgery segment posted double-digit revenue growth and a 17% year-over-year bookings increase, driving upside earnings surprise and outperforming peers. Short interest on Novanta shares jumped 21.5% to 3.57 million shares at January-end, representing 10.1% of float and signaling rising bearish bets.
1. Q4 Earnings Strong Performance
Novanta’s Q4 2025 results were powered by its Advanced Surgery business, which delivered double-digit revenue growth and a 17% year-over-year rise in bookings, reflecting robust future demand as customer inventories normalize.
2. Surge in Short Interest
By January 30th, Novanta’s short interest climbed 21.5% to 3,567,207 shares, equivalent to 10.1% of the company’s float, indicating growing bearish sentiment among market participants.
3. Stock Performance and Valuation
Shares closed at $145.63 on February 18th, marking a 5.29% gain over the past month and a 1.98% rise over twelve months, with a market capitalization near $5.2 billion.